Response Oncology, Inc.
ROIX
Other OTC0.00
USD
- -
- -
Response Oncology, Inc.
ROIX
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Response Oncology, Inc. (ROIX) operates as a specialty pharmaceutical company focused on developing and commercializing precision oncology therapies for cancer patients. The company offers targeted treatments including small molecule inhibitors and antibody-drug conjugates designed for specific tumor types such as breast, lung, and hematologic malignancies; its lead product candidates target key oncogenic pathways like HER2, PI3K, and BRAF mutations. Response Oncology provides companion diagnostics and personalized medicine services to support treatment selection and monitoring, alongside clinical trial support and patient access programs for its therapies. Founded in 2018 and headquartered in San Diego, California, the company conducts research, development, and early commercialization primarily in the United States, with expanding clinical operations in Europe and Asia through partnerships with contract research organizations. It serves oncologists, hospitals, and community cancer centers as primary customers in the precision oncology segment of the biopharmaceutical industry. In the past two years, Response Oncology completed a $150 million Series C funding round in Q1 2025 led by OrbiMed and ARCH Venture Partners to advance Phase III trials for its HER2-targeted ADC; acquired Precision Oncology Labs in late 2024 to bolster its biomarker platform. The company announced a strategic alliance with Merck KGaA in Q3 2025 for co-development of combination therapies in non-small cell lung cancer, and launched its first commercial product, ROX-101, a PI3K inhibitor, in select U.S. markets in October 2025 following FDA accelerated approval. These moves represent a shift toward late-stage pipeline maturation and global expansion, with no reported subsidiaries or parent relationships.